HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A2390 Tesnatilimab (Anti-NKG2D / CD314) Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD. Human IgG4SP
A2392 Enfortumab (Anti-Nectin-4) Enfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD. Human IgG1
A2393 Lorvotuzumab (Anti-NCAM1 / CD56) Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD. Human IgG1
A2394 Ensituximab (Anti-MUC5AC) Ensituximab (Anti-MUC5AC) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC with specificity for colorectal and pancreatic cancer. MW: 145.5 kD. Human IgG1
A2395 Imaprelimab (Anti-MUC18 / MCAM / CD146) Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD. Human IgG1
A2396 Abagovomab (Anti-MUC16) Abagovomab (Anti-MUC16) is a murine IgG1 monoclonal anti-idiotype antibody containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125 with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2398 Narnatumab (Anti-MSPR / RON / CD136) Narnatumab (Anti-MSPR / RON / CD136) is a fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor) with potential antineoplastic activity. MW: 145.5 kD. Human IgG1
A2399 Andecaliximab (Anti-MMP9) Andecaliximab (Anti-MMP9) is a recombinant chimeric IgG4 monoclonal antibody (mAb) that targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. MW: 145.5 kD. Human IgG4SP
A2400 Imalumab (Anti-MIF) Imalumab (Anti-MIF) is a human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory, and antineoplastic activities. MW: 145.5 kD. Human IgG1
A2401 Amatuximab (Anti-Mesothelin) Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD. Human IgG1
A2402 Anti-Melanotransferrin / CD228 Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD. Human IgG1
A2403 Narsoplimab (Anti-MASP2) Narsoplimab (Anti-MASP2) is a monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. MW: 145.5 kD. Human IgG4SP
A2404 Ontamalimab (Anti-MADCAM1) Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 kD. Human IgG2SA
A2405 Lupartumab (Anti-LYPD3 / C4.4A) Lupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD. Human IgG1
A2406 Anti-Ly6E  Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD. Human IgG2SA
A2407 Samrotamab (Anti-LRRC15 / LIB) Samrotamab (Anti-LRRC15 / LIB) is a fully human monoclonal antibody against LRRC15. MW: 145.5 kD. Human IgG1
A2408 Simtuzumab (Anti-LOXL2) Simtuzumab (Anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2) with potential antineoplastic activity. MW: 145.5 kD. Human IgG4SP
A2409 Ladiratuzumab (Anti-LIV-1 / SLC39A6) Ladiratuzumab (Anti-LIV-1 / SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. MW: 145.5 kD. Human IgG1
A2410 Opicinumab (Anti-LINGO1) Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential applications in acute optic neuritis and relapsed multiple sclerosis. MW: 145.5 kD. Human IgG1
A2046 Risankizumab (anti-IL-23) Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease. human IGg1, κ